Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 56 Fallopian Tube Neoplasms 25 Breast Neoplasms 18 Neoplasms 14 Carcinoma, Ovarian Epithelial 14 Multiple Myeloma 9 Neoplasm Metastasis 7 Triple Negative Breast Neoplasms 3 Recurrence 3 Peritoneal Neoplasms 3 Lung Neoplasms 3 Colorectal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Carcinoma 3 Solid Tumors 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Pancreatic Neoplasms 2 Ovarian Cancer Recurrent 2 Liver Neoplasms 2 Kidney Neoplasms 2 Endometrial Neoplasms 2 Disease Progression 2 Vaccinia 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Sarcoma 1

Interventions

Gemcitabine 2 valrubicin 1 pembrolizumab 1 liposomal doxorubicin 1 fludarabine phosphate 1 fludarabine 1 atezolizumab 1 Tumor Necrosis Factor-alpha 1 Oncolytic Virotherapy 1 Mitomycin 1 Interferons 1 Interferon-beta 1 Immune Checkpoint Inhibitors 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Adenoviridae Infections × liposomal doxorubicin × Clear all

NCT05271318 2026-05-05

PROTA

TILT Biotherapeutics Ltd.

Phase 1/2 Active not recruiting

Adenoviridae Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡